NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced that Peter Caldini, Chief Executive Officer, and Raj Denhoy, Chief Financial Officer, will present at the 44th Annual J.P Morgan Healthcare Conference on January 14, 2026 at 9:45 a.m. PT. A live webcast of the presentation will be available on the Establishment Labs.
Establishment Labs files Motiva breast implants with the FDA for reconstruction, targeting expansion beyond elective augmentation into a clinically necessary market.
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced that it has submitted Motiva® implants for approval in primary and revision breast reconstruction to the U.S. Food and Drug Administration (FDA). The products were previously approved by the FDA for use in breast augmentation on September 27, 2024. “Expanding our FD.
Establishment Labs (NASDAQ: ESTA - Get Free Report) and Omada Health (NASDAQ: OMDA - Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, earnings, profitability, analyst recommendations, valuation and risk. Earnings and Valuation This table compares Establishment Labs
XWELL (NASDAQ: XWEL - Get Free Report) and Establishment Labs (NASDAQ: ESTA - Get Free Report) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, analyst recommendations, risk, institutional ownership and dividends. Volatility and Risk XWELL has a beta of 1.23,
Shares of Establishment Labs Holdings Inc. (NASDAQ: ESTA - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the eight research firms that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in the Jefferies 2025 London Healthcare Conference. Peter Caldini, Chief Executive Officer, and Raj Denhoy, Chief Financial Officer, are scheduled to present in a fireside chat on Wednesday, November 19, 2025 at 8:30 a.m. GMT. A live webcast of the.
Establishment Labs Holdings Inc. ( ESTA ) Q3 2025 Earnings Call November 5, 2025 8:30 AM EST Company Participants Rajbir Denhoy - Chief Financial Officer Filippo Caldini - CEO & Director Conference Call Participants Anthony Petrone - Mizuho Americas LLC Joshua Jennings - TD Cowen, Research Division K. Gong - JPMorgan Chase & Co, Research Division Sam Eiber - BTIG, LLC, Research Division Mason Carrico - Stephens Inc., Research Division Michael Matson - Needham & Company, LLC, Research Division Presentation Operator Good afternoon.
Establishment Labs Holdings Inc. (ESTA) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to a loss of $0.59 per share a year ago.
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the third quarter ended September 30, 2025. Third Quarter Highlights and Outlook (Unaudited) Third quarter worldwide revenue of $53.8 million, an increase of 33.8% from the year ago period. Revenue included $11.9 million of Motiva sales in the.
